John McLaughlin - Chairman
Co-founder
Mr. McLaughlin is President and CEO of Corgentech, Inc., a privately held biopharmaceutical company. Prior to joining Corgentech, Mr. McLaughlin was president of Tularik, a publicly traded biopharmaceutical company, where he was responsible for all management functions other than research. Mr. McLaughlin held a number of senior management positions at Genentech, including Executive Vice President, with responsibility for planning functions, commercial development and business development. Mr. McLaughlin served as a counsel to the House committee responsible for drafting several of the FDA statutes, including those governing orphan drugs, generic drug approvals, patent term extensions and export of unapproved drugs from the United States. He previously practiced law in Washington, D.C. and holds a J.D. degree from Catholic University.
Srinivas Akkaraju, M.D., Ph.D.
Dr. Akkaraju joined the Life Sciences team in the Healthcare Group at J.P. Morgan Partners, LLC in April 2001. From October 1998 to April 2001, he was in the Business and Corporate Development group at Genentech, Inc., most recently as Senior Manager. There Dr. Akkaraju was responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects. In addition to his business development role, he also served for the last year as Project Team Leader for one of Genentech's clinical development products. During this time, Dr. Akkaraju was also a founding member of BioStreet, an online marketplace for biotech opportunities. Prior to joining Genentech in 1998, Dr. Akkaraju was a graduate student at Stanford University, where he earned his M.D. and Ph.D. in Immunology. Dr. Akkaraju earned his undergraduate degrees in Biochemistry and Computer Science from Rice University in 1990.
Marty Glick
Co-founder
Mr. Glick is currently Executive Vice President and Chief Financial Officer of Theravance, Inc., a biopharmaceutical company based in South San Francisco, CA. Prior to joining Advanced Medicine, he worked for ten years with Genentech, Inc., most recently as a Vice President of Finance. Mr. Glick also served on the Board of Trustees of the Foundation for Fighting Blindness - one of the leading foundations in the world supporting eye research - and on a business board advising Stanford University's Department of Ophthalmology. Mr. Glick has over 28 years of business experience with an emphasis on pharmaceutical finance.
David R. Guyer, M.D.
Chief Executive Officer; Co-founder
Author of over 100 publications, Dr. Guyer is a recognized international authority on macular diseases, particularly the use of anti-angiogenic drugs for treating AMD and DME. His academic title is Professor at the New York University School of Medicine. Dr. Guyer was the Study Co-chairman of the Pharmacological Therapy for Macular Degeneration Study Group, a 45-center worldwide group of retinal specialists studying drug therapy for AMD. This Study Group performed the first Phase III study of a drug for AMD. He has served as a consultant on ophthalmic products to more than twelve different pharmaceutical companies. He has also served as Chairman of the Research Committee of the Macula Society - one of the most renowned societies of retinal specialists in the world. Dr. Guyer was an ophthalmology resident at the Wilmer Eye Institute at Johns Hopkins Hospital and did his fellowship training in retinal surgery at the Massachusetts Eye and Ear Infirmary, the teaching affiliate of Harvard Medical School, where he was a Heed-Knapp Fellow. He received his M.D. from the Johns Hopkins University School of Medicine and his undergraduate degree from Yale College.
Michael Mullen
Michael Mullen is currently President of Bellevue Research, Inc., the U.S. research arm of Bellevue Asset Management of Zug, Switzerland. He is also a portfolio manager for BB Biotech, an investment company focused on public and private biotechnology companies in the United States and Europe. Prior to joining Bellevue in 1999, Mr. Mullen was with Cowen & Co. where he was a partner, managing director, and senior research analyst in medical technology for nine years. He is a chartered financial analyst (CFA) with a bachelor's degree from Fordham University and MBA in Finance from Indiana University.
Samir Patel, M.D.
Co-founder
Dr. Patel was trained in retinal surgery at the Massachusetts Eye and Ear Infirmary-the teaching affiliate of Harvard Medical School. He is the Director of the Retina Service and Residency Program at the University of Chicago, where he is an associate professor. Dr. Patel was the first surgeon to perform retinal pigment epithelium transplantation in a human in this country, and has multiple abstracts and publications focused on AMD. He is also involved in numerous clinical trials in retinal diseases.
Ed Penhoet, Ph.D.
Edward E. Penhoet is Dean of the School of Public Health and Professor of Public Health and of Molecular and Cell Biology at the University of California at Berkeley. Dr. Penhoet is also a director and co-founder of Chiron Corporation, one of the world’s leading biotechnology companies. Dr. Penhoet served as Chiron’s President and Chief Executive Officer from the time he co-founded the company in 1981 until April 30, 1998. Dr. Penhoet is a past Chairman of the California Health Care Institute, of the Chabot Space & Science Center, and of the Bay Area Bioscience Center. He is a member of the Boards of Directors of the Bay Area Council, the Oakland Museum Foundation, the UC System Biotech Advisory Committee, Kaiser Permanente, and the Advisory board for the Lester Center for Entrepreneurship and Innovation at UC Berkeley. He is also a member of the boards of Renovis, Inc., Zymogenetics, Inc., and Chiron Corp. He is a member of the American Society of Biological Chemists, and has published more than 50 scientific articles and papers.
Henry Simon
Henry Simon joined Schroder Ventures in London in 1987 as head of the venture capital group which developed a life sciences business in the UK. He was CEO of the life sciences team until 1996 and is now executive chairman. Mr Simon is chairman of Leicaicrosystems and Zarlink Semiconductor. He was previously chairman of Shire Pharmaceuticals and Chiroscience. Previously, Mr. Simon was president of Technicon, a diagnostics manufacturer and Vice President of ITT Europe. He started his career at Bell Laboratories after graduating from the Institute of Technology in Munich, Germany and the Royal Institute of Technology in Stockholm, Sweden.
Damion E. Wicker, M.D.
Dr. Wicker is currently a Partner with JP Morgan Partners. Dr. Wicker received a B.S. with honors from M.I.T in 1983, an M.D. from Johns Hopkins in 1987, and holds an MBA from the Wharton School of the University of Pennsylvania. Prior to joining Chase Capital Partners (CCP), Dr. Wicker was President of Adams Scientific and held positions with MBW Venture Partners and Alexon, Inc. Dr. Wicker was also a Commonwealth Fund Medical Fellow for the National Institute of Health. He is currently a member of the NVCA Life Science Group Board and the Board of Trustees of the New York Academy of Medicine. Dr. Wicker is also a Director of DW Orthopedics, Genomic Solutions, MediChem Life Sciences, Neuron Therapeutics, Optiscan Biomedical, Transurgical, Vitagen and V.I. Technologies.
|
